1. Lyons AS, Petrucelli RJ. Ilustrowana historia medycyny. Wyd. Penta. Warszawa 1996.

2. Abouassaly R, Thompson IM, Platz EA, Klein EA. Epidemiology, etiology, and prevention of prostate cancer, w: Campbell-Walsh Urology. Saunders. Philadelphia 2013:2704-2725.

3. Wojciechowska U,Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2010 roku. Centrum Onkologii. Warszawa 2013.

4. Nelson WG, De Marzo A, Isaacs W. Prostate cancer. N Engl J Med 2003; 349:366-381.

5. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-183.

6. Dutkiewicz S. Rak stercza (105-120). W: Dutkiewicz S. red. Choroby stercza (gruczołu krokowego). Wyd. Med. Termedia. Poznań 2010.

7. Husband J, Reznek R. Imaging in oncology. Taylor and Francis. London 2004: 375-400.

8. Soloway MS, Soloway CT, Williams S, et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU INT 2008;101:165-169.

9. Rees J, Patel B, Macdonagh R. Cryosurgery for prostate cancer. BJU Int2004;93: 710-714.

10. Crouzet S, Chapelon JY, Rouviere O. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol 2014; 65:907-914.

11. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. The Prostate 2004; 61(4): 332-353.

12. Goldberg H,Baniel J, Yossepowitch O. Defining high-risk prostate cancer. Cur Opin Urol 2013; 23: 337-341.

13. Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol 2010; 2: 107-123.

14. Huggins C, Hodges CV. Studies on prostate cancer I:The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer res 1941; 1: 293-297.

15. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer II: The effect of castrationon advanced carcinoma of the prostate gland. Arch Surg 1941; 43:209-223.

16. Dutkiewicz S. Hormonoterapia (135-142) w: Dutkiewicz S. red. Choroby stercza(gruczołu krokowego). Wyd. Med. Termedia. Poznań 2010.

17. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single – therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 137:566-577.

18. Crawford ED, Tombal B, Miller K, Boccon-Gibod L. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011; 186:889-897.

19. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007; 51: 306-314.

20. Wirth M, Tyrrel C, delaere K, et al. Bicalutamide (Casodex) 150 mg plus standard care in early nonmetastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years follow-up. Prostate Cancer Prostatic Dis 2007; 10(1):87-93.

21. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355: 1491-1498.

22. Akakura K, Bruchovsky N, GoldenbergSL, et al. Effects of intermittent androgen suspension on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-2790.

23. Hussain M, Tangen CM, Bery DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N.Engl J Med 2013; 368: 1314-1325.

24. Tombal B. Intermittent androgen deprivation therapy:conventional wisdom versus evidence. Eur Urol 2009; 55: 1278-1280.

25. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59.

26. Petrylak DP, Tangen CM, Hussain MH,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.

27. Tannock IF, deWit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.

28. De Bono JS, Oudard S,Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration- resistant prostate cancer progressing after docetaxel treatment: a randomized open – label trial. LANCET 2010; 376:1147-1154.

29. De Bono JS, Logothetis CJ, Fizazi K, et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS)in patients with metastatic castration resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy : results of COU-AA-301, a randomized double –blind placebo-controlled Phase III study. Ann Oncol 2010; 21 (supl 8): LBA5.

30. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.

31. Nadiminty N, Gao AC. Mechanisms of persistent activation of the androgen receptor In CRPC: recent advances and future perspectives. World J Urol 2012; 30: 287-295.

32. Vis AN, Schroder FH. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int 2009; 104: 438-448.

33. Ferraldeschi R, Pezaro C, KaravasilisV, de Bono J. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. Annu Rev Med 2013; 64: 1-13.

34. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.

35. Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014; 25:429-434.

36. Kantoff PW, Higano CS, Shore ND, et al. sipuleucel-T immunotherapy for castration-resistent prostate cancer.N Engl J Med 2010; 363: 411-422.

37. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic , asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.

38. Rabow M, Lee M. Palliative care in castrate resistant prostate cancer. Urol Clin N Am 2012; 39: 491-503.

39. HeidenreichA, Bastian PJ, Bellmunt J, et al. EAU Guidelines on prostate cancer. Part 2: treatment of advanced, relasing and castration resistant prostate cancer – update 2013. Eur Urol 2014; 65: 467-479.

40. Dutkiewicz S. Leczenie paliatywne (135-146). W: Dutkiewicz S. red. Choroby stercza(gruczołu krokowego). Wyd. Med. Termedia. Poznań 2010.